Our corporate strategy has four distinct focus areas in which we operate. It is build on our purpose, the Novo Nordisk Way and our ambition to be a sustainable business. We aim to strengthen our treatment options in diabetes and obesity care, secure leading positions within rare blood and endocrine disorders, and establish a strong presence in other serious chronic diseases such as NASH, cardiovascular disease and Alzheimer’s disease, and provide curative therapies based on our stem cell platform. Succeeding in this will ensure diversified sources of growth to drive sustainable growth for Novo Nordisk.
million people live with diabetes
million people live with obesity
thousand people live with haemophilia